Search research articles
Contact Us
Filters
Showing results (341-350 of 703) with videos related to
Page
of 71
Sort By:
Science Translational Medicine
|
April 27, 2022
Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors
Paulien Kaptein, Celia Jacoberger-Foissac, Petros Dimitriadis, et al.
Cancers
|
November 18, 2020
Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma
Elena Shklovskaya, Jenny H Lee, Su Yin Lim, et al.
The Oncologist
|
March 13, 2020
The Impact of Nonsteroidal Anti-Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti-PD-1 Therapy in Advanced Melanoma
Daniel Y Wang, Jennifer L McQuade, Rajat R Rai, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 13, 2019
Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients
J H Lee, R P Saw, J F Thompson, et al.
Nature Communications
|
August 26, 2018
SIRT6 haploinsufficiency induces BRAF<sup>V600E</sup> melanoma cell resistance to MAPK inhibitors via IGF signalling
Thomas Strub, Flavia G Ghiraldini, Saul Carcamo, et al.
Plos One
|
September 9, 2017
Differential regulation of innate immune cytokine production through pharmacological activation of Nuclear Factor-Erythroid-2-Related Factor 2 (NRF2) in burn patient immune cells and monocytes
Timothy K Eitas, Wesley H Stepp, Lucas Sjeklocha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 20, 2019
Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials
Jarem Edwards, Annie Tasker, Inês Pires da Silva, et al.
Plos One
|
November 3, 2017
Correction: Differential regulation of innate immune cytokine production through pharmacological activation of Nuclear Factor-Erythroid-2-Related Factor 2 (NRF2) in burn patient immune cells and monocytes
Timothy K Eitas, Wesley H Stepp, Lucas Sjeklocha, et al.
Frontiers in Immunology
|
August 25, 2022
Detailed spatial immunophenotyping of primary melanomas reveals immune cell subpopulations associated with patient outcome
Grace H Attrill, Hansol Lee, Annie T Tasker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 10, 2017
Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib
Georgina V Long, Zeynep Eroglu, Jeffrey Infante, et al.
Page
of 71
Search research articles
Search
Showing results (341-350 of 703) with videos related to
Sort By:
Page
of 71
Science Translational Medicine
|
April 27, 2022
Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors
Paulien Kaptein, Celia Jacoberger-Foissac, Petros Dimitriadis, et al.
Cancers
|
November 18, 2020
Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma
Elena Shklovskaya, Jenny H Lee, Su Yin Lim, et al.
The Oncologist
|
March 13, 2020
The Impact of Nonsteroidal Anti-Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti-PD-1 Therapy in Advanced Melanoma
Daniel Y Wang, Jennifer L McQuade, Rajat R Rai, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 13, 2019
Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients
J H Lee, R P Saw, J F Thompson, et al.
Nature Communications
|
August 26, 2018
SIRT6 haploinsufficiency induces BRAF<sup>V600E</sup> melanoma cell resistance to MAPK inhibitors via IGF signalling
Thomas Strub, Flavia G Ghiraldini, Saul Carcamo, et al.
Plos One
|
September 9, 2017
Differential regulation of innate immune cytokine production through pharmacological activation of Nuclear Factor-Erythroid-2-Related Factor 2 (NRF2) in burn patient immune cells and monocytes
Timothy K Eitas, Wesley H Stepp, Lucas Sjeklocha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 20, 2019
Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials
Jarem Edwards, Annie Tasker, Inês Pires da Silva, et al.
Plos One
|
November 3, 2017
Correction: Differential regulation of innate immune cytokine production through pharmacological activation of Nuclear Factor-Erythroid-2-Related Factor 2 (NRF2) in burn patient immune cells and monocytes
Timothy K Eitas, Wesley H Stepp, Lucas Sjeklocha, et al.
Frontiers in Immunology
|
August 25, 2022
Detailed spatial immunophenotyping of primary melanomas reveals immune cell subpopulations associated with patient outcome
Grace H Attrill, Hansol Lee, Annie T Tasker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 10, 2017
Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib
Georgina V Long, Zeynep Eroglu, Jeffrey Infante, et al.
Page
of 71